Nov 09, 2022 / 05:40PM GMT
Michael Leonidovich Ryskin - BofA Securities, Research Division - Director in Equity Research & Research Analyst
Great. Thank you for joining us, everyone. Let's try this again. For those of you that don't know me, I'm Mike Ryskin. I'm on the Life Science Tools and Diagnostics team here at Bank of America. And joining us for our next session, we're excited to have Andrew Hopkins, CEO and Founder of Exscientia. And as you can probably tell, it's a little bit of a different flavor to the next panel we're doing. This is -- the focus of this chat is going to be on artificial intelligence and drug discovery.
So Andrew, thanks so much for joining us.
Andrew L. Hopkins - Exscientia plc - Founder, CEO & Executive Director
Great to be here, Mike. Thanks much.
Questions and Answers:
Michael Leonidovich Ryskin - BofA Securities, Research Division - Director in Equity Research & Research AnalystGreat. And the format of the session is going to be similar to what you've seen in some of your other talks
Trustpilot
